Janux Therapeutics, Inc. Financing Receivable, Accrued Interest, before Allowance for Credit Loss
Janux Therapeutics, Inc. (JANX) had Financing Receivable, Accrued Interest, before Allowance for Credit Loss of $6.20 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Credit Losses
us-gaap:FinancingReceivableAccruedInterestBeforeAllowanceForCreditLoss · last filed 2026-08-06
- 2026-06-30: Financing Receivable, Accrued Interest, before Allowance for Credit Loss $6.20M.
- 2026-03-31: Financing Receivable, Accrued Interest, before Allowance for Credit Loss $7.50M.
- 2025-12-31: Financing Receivable, Accrued Interest, before Allowance for Credit Loss $6.40M.
- 2025-09-30: Financing Receivable, Accrued Interest, before Allowance for Credit Loss $6.30M.
| Period end | Financing Receivable, Accrued Interest, before Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $6.20M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $7.50M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $6.40M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $6.30M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $5.70M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $5.60M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $5.40M 10-K · filed 2026-02-26 |
| 2024-09-30 | $4.50M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $4.60M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $3.90M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $2.20M 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.70M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $1.50M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $700.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $700.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | $300.00K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $300.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | $100.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | $200.00K 10-K · filed 2023-03-10 |
| 2021-09-30 | $28.00M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $3.00K 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |